First Tracks Biotherapeutics (HAM:B43) Book Value per Share: €10.76 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €37.60
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Book Value per Share?

First Tracks Biotherapeutics HAM:B43 -2.84% 20 Book Value per Share is €10.76 as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

First Tracks Biotherapeutics's book value per share for the quarter that ended in Dec. 2024 was €10.76.

During the past 12 months, First Tracks Biotherapeutics's average Book Value Per Share Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

First Tracks Biotherapeutics's current price is €37.60. Its book value per share for the quarter that ended in Dec. 2024 was €10.76. Hence, today's PB Ratio of First Tracks Biotherapeutics is 3.49.

During the past 2 years, the highest P/B Ratio of First Tracks Biotherapeutics was 3.92. The lowest was 0.00. And the median was 0.00.

First Tracks Biotherapeutics  (HAM:B43) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

First Tracks Biotherapeutics Book Value per Share Related Terms

First Tracks Biotherapeutics Book Value per Share Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Book Value per Share Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Book Value per Share
10.82 10.76

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Book Value per Share 10.82 10.76

HAM:B43 vs AVLN, IMTX, ARDX: Book Value per Share Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

First Tracks Biotherapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's PB Ratio falls into.


HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Book Value per Share Calculation

First Tracks Biotherapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(373.97-0.00)/34.75
=10.76

First Tracks Biotherapeutics's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(373.97-0.00)/34.75
=10.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of €10.76 mean?
First Tracks Biotherapeutics (HAM:B43) has a Book Value per Share of €10.76 as of Dec. 2024. Book value per share gives the per-share value of a company's stockholder equity. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Book Value per Share too high?
First Tracks Biotherapeutics' current Book Value per Share is €10.76. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Book Value per Share compare to AVLN and IMTX?
First Tracks Biotherapeutics' Book Value per Share of €10.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Book Value per Share is €10.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Book Value per Share of €10.76. The current Book Value per Share is €10.76. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Book Value per Share is €10.76 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.60
Price